Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Natera, Inc.

< Previous 1 2 3 4 5 Next >
Natera Submits First PMA Module to the FDA for Signatera™
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Senior Leadership Appointments
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Pricing of $250 Million Follow-On Offering
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Launches Proposed Follow-On Offering
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Second Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Files Patent Infringement Suit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its Second Quarter 2023 Results on August 3rd
From Natera, Inc.
Via Business Wire
Tickers NTRA
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
From Natera, Inc.
Via Business Wire
Tickers NTRA
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
From Natera, Inc.
Via Business Wire
Tickers NTRA
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports First Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces First Quarter 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
Tickers NTRA
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Commercial Payor Coverage for Signatera™
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Tickers NTRA
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
From Natera, Inc.
Via Business Wire
Tickers NTRA
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
From Natera, Inc.
Via Business Wire
Tickers NTRA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.